Form 4: Quest Diagnostics Executive Increases Stake via Dividend

SVP Patrick Plewman acquired 49 shares of Quest Diagnostics common stock through a dividend reinvestment plan.

Summary

• Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, acquired 49 shares of common stock.
• The transaction occurred on April 20, 2026, at a price of $194.699 per share.
• The acquisition was executed through a dividend reinvestment plan.
• Following this transaction, the reporting person holds a total of 15,247 shares of Quest Diagnostics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing reflecting standard dividend reinvestment activity.

Positives

• Insider demonstrates commitment to the company by increasing equity holdings.
• The acquisition was facilitated through a standard dividend reinvestment plan, indicating long-term holding intent.

Negatives

• None identified; this is a routine administrative transaction.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

Not applicable; this is a retrospective disclosure of a completed transaction.

Industry Context

StockSavvy.ai notes that routine insider acquisitions via dividend reinvestment plans are common corporate practices and generally do not signal a change in strategic direction or material non-public information.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and equity ownership practices observed in large-cap healthcare companies.
• Dividend reinvestment is a standard mechanism for long-term equity accumulation by corporate officers.

Stakeholder Impact

• Minimal impact on shareholders as this is a small-scale acquisition via a dividend reinvestment plan.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Dividend Reinvestment